Cost of treating rare genetic blindness: $425,000 per eye

Treatment of a rare, inherited form of blindness will cost $425,000 per eye, the company bringing the therapy to market announced on Wednesday.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

CONCLUSIONS: In elderly patients even with comorbidities, both laparoscopic ventral rectopexy and stapled transanal rectal resection are safe and can improve function of the anorectum in patients with obstructed defecation attributed to structural abnormalities. Laparoscopic ventral rectopexy has better long-term functional outcome, less complications, and less recurrences compared with stapled transanal rectal resection. Perineal descent only improves after laparoscopic ventral rectopexy. Stapled transanal rectal resection was shown not to be the first choice in elderly patients with obstructed defecation unless they ha...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions Source Type: research
ConclusionsThe prevalence of diabetic retinopathy in this paediatric population was 11%. Early age at diagnosis and poor metabolic control are independent risk factors for diabetic retinopathy.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Experts accused Michel Sidib é , the agency ’ s chief, of having an autocratic style leading to “ ethical blindness ” on harassment and the abuse of power.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Acquired Immune Deficiency Syndrome UNAIDS United Nations Sexual Harassment #MeToo Movement Ethics and Official Misconduct Michel Sidibe Source Type: news
Cyanin Chloride Inhibits Hyperbaric Pressure-Induced Decrease of Intracellular Glutamate-Aspartate Transporter in Rat Retinal Müller Cells. J Ophthalmol. 2018;2018:6128470 Authors: Chen X, Wang Y, Han F, Ke M Abstract Purpose: Glaucoma is the leading cause of irreversible blindness throughout the world. The pathogenesis of glaucoma is complex, and neuroprotection is a crucial aspect of therapy. High concentrations of extracellular glutamate are toxic to the optic nerve. The glutamate-aspartate transporter (GLAST) in retinal Müller cells is involved in the development of glaucoma. Anthocyanin ...
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
Source: Intensive Care Medicine - Category: Intensive Care Source Type: research
Conclusions: Artificial reproduction of Descemet membrane with respect to topography and similar stiffness offers a potential innovative way to bioengineer a functional CEC monolayer from autologous stem cells.
Source: Cornea - Category: Opthalmology Tags: Basic Investigation Source Type: research
(Children's Hospital of Philadelphia) Children's Hospital of Philadelphia celebrates a pivotal moment in medicine: approval by the European Commission of LUXTURNA ® (voretigene neparvovec), the first and only gene therapy for patients with an inherited retinal disease, last month. This also makes LUXTURNA the first gene therapy for a genetic disease that has received regulatory approval in both the US and European Union.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
The FDA has signed off on Cambridge startup Editas Medicine's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Editas (Nasdaq: EDIT) said that the FDA approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments of DNA. The study, which Editas…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
(Natural News) In the U.S., more people lose their vision because of age-related macular degeneration than glaucoma and cataracts combined, says the National Institute of Health (NIH). This makes the condition the leading cause of blindness among people older than 60. Macular degeneration is irreversible, but there are steps you can take to lower your...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
More News: Blindness | Genetics | Health | Opthalmology